Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens

Liesel M. Fitzgerald, Chol Hee Jung, Ee Ming Wong, Ji Hoon E. Joo, Jodee A. Gould, Vivien Vasic, Julie K. Bassett, Neil O'Callaghan, Tim Nottle, John Pedersen, Graham G. Giles, Melissa C. Southey

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Prognostic genomic biomarkers that can be measured at diagnosis to aid choice of treatment options are unavailable for most common cancers. This is due in part to the poor quality and quantity of available diagnostic specimens for discovery research and to limitations in genomic technologies. Recent technical advances now enable high-density molecular analyses using suboptimal biological specimens. Here we describe the optimization of a transcriptome-specific protocol for use with formalin-fixed, paraffin-embedded (FFPE) diagnostic prostate cancer (PrCa) specimens. We applied the Ion AmpliSeq Transcriptome Human Gene Expression Kit (AmpliSeq Kit) to RNA samples extracted from 36 tumor-enriched and 16 adjacent normal tissues (ADJNT) from 37 FFPE PrCa specimens over a series of eight pilot studies, incorporating protocol modifications from Pilots 2 to 5. Data quality were measured by (1) the total number of mapped reads; (2) the percentage of reads that mapped to AmpliSeq target regions (OnTarget%); (3) the percentage of genes on the AmpliSeq panel with a read count ≥10 (TargetsDetected%); and (4) comparing the gene read-count distribution of the prostate tissue samples with the median gene read-count distribution of cell line-derived RNA samples. Modifications incorporated into Pilot study 5 provided gene expression data equivalent to cell line-derived RNA samples. These modifications included the use of freshly cut slides for macrodissection; increased tissue section thickness (8 μm); RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher); 18 target amplification cycles; and processing six samples per Ion PI chip. This protocol will facilitate the discovery of prognostic biomarkers for cancer by allowing researchers to exploit previously underutilized diagnostic FFPE specimens.

Original languageEnglish
Pages (from-to)537-550
Number of pages14
JournalLaboratory Investigation
Volume98
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Cite this

Fitzgerald, Liesel M. ; Jung, Chol Hee ; Wong, Ee Ming ; Joo, Ji Hoon E. ; Gould, Jodee A. ; Vasic, Vivien ; Bassett, Julie K. ; O'Callaghan, Neil ; Nottle, Tim ; Pedersen, John ; Giles, Graham G. ; Southey, Melissa C. / Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens. In: Laboratory Investigation. 2018 ; Vol. 98, No. 4. pp. 537-550.
@article{1bef599c68134a94a1aba67daf520153,
title = "Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens",
abstract = "Prognostic genomic biomarkers that can be measured at diagnosis to aid choice of treatment options are unavailable for most common cancers. This is due in part to the poor quality and quantity of available diagnostic specimens for discovery research and to limitations in genomic technologies. Recent technical advances now enable high-density molecular analyses using suboptimal biological specimens. Here we describe the optimization of a transcriptome-specific protocol for use with formalin-fixed, paraffin-embedded (FFPE) diagnostic prostate cancer (PrCa) specimens. We applied the Ion AmpliSeq Transcriptome Human Gene Expression Kit (AmpliSeq Kit) to RNA samples extracted from 36 tumor-enriched and 16 adjacent normal tissues (ADJNT) from 37 FFPE PrCa specimens over a series of eight pilot studies, incorporating protocol modifications from Pilots 2 to 5. Data quality were measured by (1) the total number of mapped reads; (2) the percentage of reads that mapped to AmpliSeq target regions (OnTarget{\%}); (3) the percentage of genes on the AmpliSeq panel with a read count ≥10 (TargetsDetected{\%}); and (4) comparing the gene read-count distribution of the prostate tissue samples with the median gene read-count distribution of cell line-derived RNA samples. Modifications incorporated into Pilot study 5 provided gene expression data equivalent to cell line-derived RNA samples. These modifications included the use of freshly cut slides for macrodissection; increased tissue section thickness (8 μm); RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher); 18 target amplification cycles; and processing six samples per Ion PI chip. This protocol will facilitate the discovery of prognostic biomarkers for cancer by allowing researchers to exploit previously underutilized diagnostic FFPE specimens.",
author = "Fitzgerald, {Liesel M.} and Jung, {Chol Hee} and Wong, {Ee Ming} and Joo, {Ji Hoon E.} and Gould, {Jodee A.} and Vivien Vasic and Bassett, {Julie K.} and Neil O'Callaghan and Tim Nottle and John Pedersen and Giles, {Graham G.} and Southey, {Melissa C.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1038/s41374-017-0001-8",
language = "English",
volume = "98",
pages = "537--550",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "4",

}

Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens. / Fitzgerald, Liesel M.; Jung, Chol Hee; Wong, Ee Ming; Joo, Ji Hoon E.; Gould, Jodee A.; Vasic, Vivien; Bassett, Julie K.; O'Callaghan, Neil; Nottle, Tim; Pedersen, John; Giles, Graham G.; Southey, Melissa C.

In: Laboratory Investigation, Vol. 98, No. 4, 01.04.2018, p. 537-550.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens

AU - Fitzgerald, Liesel M.

AU - Jung, Chol Hee

AU - Wong, Ee Ming

AU - Joo, Ji Hoon E.

AU - Gould, Jodee A.

AU - Vasic, Vivien

AU - Bassett, Julie K.

AU - O'Callaghan, Neil

AU - Nottle, Tim

AU - Pedersen, John

AU - Giles, Graham G.

AU - Southey, Melissa C.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Prognostic genomic biomarkers that can be measured at diagnosis to aid choice of treatment options are unavailable for most common cancers. This is due in part to the poor quality and quantity of available diagnostic specimens for discovery research and to limitations in genomic technologies. Recent technical advances now enable high-density molecular analyses using suboptimal biological specimens. Here we describe the optimization of a transcriptome-specific protocol for use with formalin-fixed, paraffin-embedded (FFPE) diagnostic prostate cancer (PrCa) specimens. We applied the Ion AmpliSeq Transcriptome Human Gene Expression Kit (AmpliSeq Kit) to RNA samples extracted from 36 tumor-enriched and 16 adjacent normal tissues (ADJNT) from 37 FFPE PrCa specimens over a series of eight pilot studies, incorporating protocol modifications from Pilots 2 to 5. Data quality were measured by (1) the total number of mapped reads; (2) the percentage of reads that mapped to AmpliSeq target regions (OnTarget%); (3) the percentage of genes on the AmpliSeq panel with a read count ≥10 (TargetsDetected%); and (4) comparing the gene read-count distribution of the prostate tissue samples with the median gene read-count distribution of cell line-derived RNA samples. Modifications incorporated into Pilot study 5 provided gene expression data equivalent to cell line-derived RNA samples. These modifications included the use of freshly cut slides for macrodissection; increased tissue section thickness (8 μm); RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher); 18 target amplification cycles; and processing six samples per Ion PI chip. This protocol will facilitate the discovery of prognostic biomarkers for cancer by allowing researchers to exploit previously underutilized diagnostic FFPE specimens.

AB - Prognostic genomic biomarkers that can be measured at diagnosis to aid choice of treatment options are unavailable for most common cancers. This is due in part to the poor quality and quantity of available diagnostic specimens for discovery research and to limitations in genomic technologies. Recent technical advances now enable high-density molecular analyses using suboptimal biological specimens. Here we describe the optimization of a transcriptome-specific protocol for use with formalin-fixed, paraffin-embedded (FFPE) diagnostic prostate cancer (PrCa) specimens. We applied the Ion AmpliSeq Transcriptome Human Gene Expression Kit (AmpliSeq Kit) to RNA samples extracted from 36 tumor-enriched and 16 adjacent normal tissues (ADJNT) from 37 FFPE PrCa specimens over a series of eight pilot studies, incorporating protocol modifications from Pilots 2 to 5. Data quality were measured by (1) the total number of mapped reads; (2) the percentage of reads that mapped to AmpliSeq target regions (OnTarget%); (3) the percentage of genes on the AmpliSeq panel with a read count ≥10 (TargetsDetected%); and (4) comparing the gene read-count distribution of the prostate tissue samples with the median gene read-count distribution of cell line-derived RNA samples. Modifications incorporated into Pilot study 5 provided gene expression data equivalent to cell line-derived RNA samples. These modifications included the use of freshly cut slides for macrodissection; increased tissue section thickness (8 μm); RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher); 18 target amplification cycles; and processing six samples per Ion PI chip. This protocol will facilitate the discovery of prognostic biomarkers for cancer by allowing researchers to exploit previously underutilized diagnostic FFPE specimens.

UR - http://www.scopus.com/inward/record.url?scp=85040737172&partnerID=8YFLogxK

U2 - 10.1038/s41374-017-0001-8

DO - 10.1038/s41374-017-0001-8

M3 - Article

VL - 98

SP - 537

EP - 550

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 4

ER -